 JERUSALEM, Oct. 7, 2019 PRNewswire -- BiondVax Pharmaceuticals Ltd. BVXV, a phase 3 clinical stage biopharmaceutical company focused on developing and commercializing the M-001 clinical Phase 3 Universal Influenza Vaccine candidate, announced today the receipt of 4 million from the European Investment Bank EIB. Dr. Ron Babecoff, BiondVaxs President and CEO, commented, This past June we were honored to welcome EIB Vice-President Mr. Ambroise Fayolle to our manufacturing facility in Jerusalem for a signature event celebrating the extension of the EIB-BiondVax financing agreement to 24 million. 